{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:37:28Z","timestamp":1792618648288,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.coph.2024.102461","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T08:57:13Z","timestamp":1715849833000},"page":"102461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["In the heart and beyond: Mitochondrial dysfunction in heart failure with preserved ejection fraction (HFpEF)"],"prefix":"10.1016","volume":"76","author":[{"given":"Nisha","family":"Bhattarai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5929-0928","authenticated-orcid":false,"given":"Iain","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2024.102461_bib1","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.289.2.194","article-title":"Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic","volume":"289","author":"Redfield","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2024.102461_bib2","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, Borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.coph.2024.102461_sref3","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","article-title":"Cardiac energy metabolism in heart failure","volume":"128","author":"Lopaschuk","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.coph.2024.102461_bib4","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/heartjnl-2021-319605","article-title":"Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management","volume":"108","author":"Gevaert","year":"2022","journal-title":"Heart"},{"key":"10.1016\/j.coph.2024.102461_bib5","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2024.102461_bib6","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2024.102461_sref7","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2024.102461_bib8","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1056\/NEJMe2309294","article-title":"Heart failure with preserved ejection fraction - a metabolic disease?","volume":"389","author":"Pinto","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2024.102461_bib9","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1161\/CIRCULATIONAHA.119.041886","article-title":"Research priorities for heart failure with preserved ejection fraction: national heart, lung, and blood Institute working group summary","volume":"141","author":"Shah","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2024.102461_bib10","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jacc.2009.05.012","article-title":"Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency","volume":"54","author":"Phan","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.coph.2024.102461_bib29","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac544.246","article-title":"A\u00a0phase 2a trial investigating ninerafaxstat \u2013 a novel cardiac mitotrope for the treatment of diabetic cardiomyopathy (IMPROVE-DiCE)","volume":"43","author":"Hundertmark","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2024.102461_bib11","doi-asserted-by":"crossref","first-page":"H934","DOI":"10.1152\/ajpheart.00238.2018","article-title":"Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction","volume":"315","author":"Alex","year":"2018","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.coph.2024.102461_bib12","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2021.12.009","article-title":"Clinical phenotypes of heart failure with preserved ejection fraction to select preclinical animal models","volume":"7","author":"van Ham","year":"2022","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.coph.2024.102461_sref13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","article-title":"Nitrosative stress drives heart failure with preserved ejection fraction","volume":"568","author":"Schiattarella","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.coph.2024.102461_bib14","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/cvr\/cvaa256","article-title":"The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction","volume":"117","author":"Withaar","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.coph.2024.102461_bib28","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/CIRCRESAHA.120.317933","article-title":"Targeting mitochondria-inflammation circuit by \u03b2-hydroxybutyrate mitigates HFpEF","volume":"128","author":"Deng","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.coph.2024.102461_bib15","doi-asserted-by":"crossref","first-page":"H443","DOI":"10.1152\/ajpheart.00594.2022","article-title":"Combining three independent pathological stressors induces a heart failure with preserved ejection fraction phenotype","volume":"324","author":"Li","year":"2023","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.coph.2024.102461_bib16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jacbts.2020.11.012","article-title":"Novel g\u00f6ttingen miniswine model of heart failure with preserved ejection fraction integrating multiple comorbidities","volume":"6","author":"Sharp","year":"2021","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.coph.2024.102461_bib17","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1161\/CIRCRESAHA.120.317046","article-title":"NAD+ repletion reverses heart failure with preserved ejection fraction","volume":"128","author":"Tong","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.coph.2024.102461_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/cvr\/cvae006","article-title":"Mitochondrial fatty acid oxidation is the major source of cardiac ATP production in heart failure with preserved ejection fraction","author":"Sun","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.coph.2024.102461_bib19","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1161\/CIRCULATIONAHA.122.061846","article-title":"Myocardial metabolomics of human heart failure with preserved ejection fraction","volume":"147","author":"Hahn","year":"2023","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.coph.2024.102461_bib30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jacbts.2023.11.006","article-title":"Cardiac substrate utilization and relationship to invasive exercise hemodynamic parameters in HFpEF","volume":"9","author":"O\u2019Sullivan","year":"2024","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.coph.2024.102461_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s10020-018-0005-x","article-title":"Uncoupling of glycolysis from glucose oxidation accompanies the development of heart failure with preserved ejection fraction","volume":"24","author":"Fillmore","year":"2018","journal-title":"Mol Med"},{"key":"10.1016\/j.coph.2024.102461_bib21","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/gerona\/glt011","article-title":"Impaired aerobic capacity and physical functional performance in older heart failure patients with preserved ejection fraction: role of lean body mass","volume":"68","author":"Haykowsky","year":"2013","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.coph.2024.102461_bib22","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1152\/physrev.1997.77.3.731","article-title":"Cellular energy utilization and molecular origin of standard metabolic rate in mammals","volume":"77","author":"Rolfe","year":"1997","journal-title":"Physiol Rev"},{"key":"10.1016\/j.coph.2024.102461_bib23","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jchf.2016.03.011","article-title":"Skeletal muscle mitochondrial content, oxidative capacity, and Mfn2 expression are reduced in older patients with heart failure and preserved ejection fraction and are related to exercise intolerance","volume":"4","author":"Molina","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.coph.2024.102461_bib24","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamacardio.2023.0957","article-title":"Skeletal muscle mitochondrial respiration and exercise intolerance in patients with heart failure with preserved ejection fraction","volume":"8","author":"Scandalis","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.coph.2024.102461_bib25","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1126\/science.1065874","article-title":"Identification of ubiquitin ligases required for skeletal muscle atrophy","volume":"294","author":"Bodine","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.coph.2024.102461_bib26","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/jcsm.12968","article-title":"Targeting MuRF1 by small molecules in a HFpEF rat model improves myocardial diastolic function and skeletal muscle contractility","volume":"13","author":"Adams","year":"2022","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.coph.2024.102461_bib27","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1002\/ehf2.13405","article-title":"Ubiquitin-proteasome-system and enzymes of energy metabolism in skeletal muscle of patients with HFpEF and HFrEF","volume":"8","author":"Adams","year":"2021","journal-title":"ESC Heart Fail"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489224000316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489224000316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T06:31:14Z","timestamp":1715927474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489224000316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":30,"alternative-id":["S1471489224000316"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2024.102461","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In the heart and beyond: Mitochondrial dysfunction in heart failure with preserved ejection fraction (HFpEF)","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2024.102461","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102461"}}